Efficacy and safety of intrapleural instillation of Alteplase in the management of complicated pleural effusion or empyema

American Journal of Therapeutics

Volumn 14, Issue 4, 2007, Pages 341-345

  Thommi, George ^a,b   Nair, Chandra K ^a,b   Aronow, Wilbert S ^a,b   Shehan, Chris ^a,b   Meyers, Patrick ^a,b   McLeay, Matthew ^a,b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Alteplase; Empyema; Pleural effusion; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CHRONIC DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOTHORAX; HUMAN; LUNG ABSCESS; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PLEURA EMPYEMA; PRIORITY JOURNAL; THERAPY EFFECT; THORAX DRAINAGE; THORAX PAIN; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION ROUTES; EMPYEMA, PLEURAL; FEMALE; FIBRINOLYTIC AGENTS; HEMOTHORAX; HUMANS; MALE; MIDDLE AGED; PLEURAL EFFUSION; PLEURAL EFFUSION, MALIGNANT; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34547655480     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000208275.88120.d1     Document Type: Article

References (18)

1. Cohen M, Sahn SA. Resolution of pleural effusions. Chest. 2001;119:1547-1562.
2. Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia. Chest. 1978;74:170-173.
3. Hasley PB, Albaum MN, Li Y-H, et al. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med. 1996;156:2206-2212.
4. Chung C-L, Chen Y-C, Chang S-C. Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion. Chest. 2003;123:1188-1195.
5. Safvi A, Nemcek AA Jr. The use of fibrinolytic agents in drainage of complicated fluid collections. Appl Radiol. 1998;27:43-49.
6. Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of parapneumonic effusions and empyema. Cochrane Database Syst Rev. 2004; CD002312.
7. Davies RJO, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax. 1997;52:416-421.
8. Bouros D, Schiza S, Tzanakis N, et al. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema: a randomized, double- blind study. Am J Respir Crit Care Med. 1999;159:37-42.
9. Moulton JS, Moore PT, Mencini RA. Treatment of loculated pleural effusions with transcatheter intracavitary urokinase. Am J Roentgenol. 1989;153:941-945.
10. Bouros D, Schiza S, Patsourakis G, et al. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions: a prospective, double-blind study. Am J Respir Crit Care Med. 1997;155:291-295.
11. Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005;352:865-874.
12. Heffner JE. Multicenter trials of treatment for empyema - after all these years. N Engl J Med. 2005;352:926-928.
13. Thommi G, Shehan C, Bell A, et al. Intrapleural instillation of TPA in the management of complicated pleural effusions (abstract). Chest. 2000;118:S164.
14. Abbokinase® (Urokinase) prescribing information. Abbott Laboratories, North Chicago, IL. Revised October, 2002.
15. Retavase® (Reteplase, recombinant) prescribing information. Malvern, PA: Centocor, Inc, 2000.
16. Activase® (Alteplase, recombinant tissue plasminogen activator) prescribing information. Genentech, Inc, South San Francisco, CA. Revised April, 1999.
17. TNKase™ (Tenecteplase) prescribing information. South San Francisco, CA, Genentech, Inc, 2000.
18. Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest. 2000;118:1158-1171.